prizidilol: RN given refers to parent cpd; synonyms prizidilol & SK&F 92657 refer to di-HCl [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 71952 |
| CHEMBL ID | 119865 |
| SCHEMBL ID | 122856 |
| MeSH ID | M0082387 |
| Synonym |
|---|
| skf-92657 |
| prizidilol |
| prizidilol [inn:ban] |
| sk&f-92657 |
| 3(2h)-pyridazinone, 6-(2-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)-, hydrazone |
| prizidilolum [inn-latin] |
| CHEMBL119865 |
| 1-(tert-butylamino)-3-[2-(6-hydrazinylpyridazin-3-yl)phenoxy]propan-2-ol |
| 72848-98-7 |
| g29795cn0b , |
| prizidilolum |
| unii-g29795cn0b |
| 59010-44-5 |
| prizidilol [inn] |
| prizidilol [who-dd] |
| 2-propanol, 1-((1,1-dimethylethyl)amino)-3-(2-(6-hydrazino-3-pyridazinyl)phenoxy)- |
| 1-(tert-butylamino)-3-(o-(6-hydrazino-3-pyridazinyl)phenoxy)-2-propanol |
| SCHEMBL122856 |
| QGONODUKOFNSOY-UHFFFAOYSA-N |
| 3-[2-(3-t-butylamino-2-hydroxypropoxy)phenyl]-6-hydrazinopyridazine |
| Q27278646 |
| 1-(tert-butylamino)-3-(2-(6-hydrazinylpyridazin-3-yl)phenoxy)propan-2-ol |
| DTXSID80866727 |
prizidilol hydrochloride (SK&F 92657) is a novel antihypertensive agent with vasodilating and beta-adrenoreceptor blocking properties. Isoprenaline heart rate dose-response curves showed parallel shifts to the right after oral prizIDilol, indicating antagonism by this compound at beta- adrenoceptors in the heart.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The effects of SK & F 92657 on resting flow and on the dose-response relationship for intra-arterial isoprenaline were studied." | ( Investigation of a combined arteriolar dilator and beta-adrenoceptor antagonist (SK & F 92657) in the peripheral vessels of man. Collier, JG; Pitcher, DW, 1980) | 0.26 |
| " 2 Isoprenaline heart rate dose-response curves showed parallel shifts to the right after oral prizidilol, indicating antagonism by this compound at beta-adrenoceptors in the heart." | ( An assessment of beta-adrenoceptor blockade in man by prizidilol hydrochloride. Curry, PV; Pitcher, DW; Trounce, JR, 1982) | 0.26 |
| "1 The effects of a single oral dose of 600 mg of prizidilol on renal function were studied 5 to 6 h after dosing in six normal subjects and eight patients with essential hypertension." | ( Acute effects of combined vasodilation and beta-adrenoceptor blockade with prizidilol on renal function. Bianchetti, MG; Boehringer, K; Link, L; Reubi, FC; Schiffl, H; Weidmann, P, 1983) | 0.27 |
| "Three different doses (50, 100 and 200 mg) of prizidilol hydrochloride (SK&F 92657), a novel antihypertensive agent with vasodilating and beta-adrenoreceptor blocking properties, were given to three (n = 5) groups of essential hypertensive patients in order to evaluate hypotensive dose-response relationship of the drug and its beta-adrenoreceptor blocking properties." | ( Dose-response relationship of prizidilol hydrochloride (SK&F 92657): a comparison between acute and chronic effects in patients with essential hypertension. Abdel-Haq, B; Leto di Priolo, S; Magagna, A; Pedrinelli, R; Salvetti, A; Simonini, N, 1984) | 0.27 |
| " The fall in blood pressure of genetically hypertensive rats was maintained during 52 days of chronic dosing with no development of tolerance." | ( Hemodynamic profile of a new antihypertensive agent D,L-3-[2-(3-t-butylamino-2-hydroxypropoxy)phenyl]-6-hydrazinopyridazine (SK&F 92657). Cameron, D; Eden, RJ; Fielden, R; Owen, DA; Taylor, EM, ) | 0.13 |
| " In patients with inadequate blood pressure response the dosage was then increased to 400 mg twice daily for 4 additional weeks." | ( Antihypertensive effect of prizidilol. Andrén, L; Hansson, L; Svensson, A, ) | 0.13 |
| " The antihypertensive effect of 4 weeks' treatment with prizidilol (SKF 92657) (mean dosage 520 mg once or twice daily) was studied in ten essential hypertensive patients." | ( Effects of prizidilol (SKF 92657) on blood pressure, haemodynamics, sympathetic nervous system activity and plasma volume in essential hypertension. Agabiti-Rosei, E; Alicandri, CL; Beschi, M; Castellano, M; Di Priolo, SL; Fariello, R; Muiesan, G; Platto, L; Romanelli, G, 1981) | 0.26 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID177366 | Dose required to produce a fall in blood pressure of 40 mmHg in the anesthetized rat | 1988 | Journal of medicinal chemistry, Feb, Volume: 31, Issue:2 | Design and synthesis of a series of combined vasodilator/beta-adrenoceptor antagonists based on 6-arylpyridazinones. |
| AID48368 | Intrinsic Sympathomimetic Activity (ISA) determined from the ratio of the maximal compound and isoprenaline induced tachycardia in anesthetized ganglion blocked cats following intravenous administration | 1988 | Journal of medicinal chemistry, Feb, Volume: 31, Issue:2 | Design and synthesis of a series of combined vasodilator/beta-adrenoceptor antagonists based on 6-arylpyridazinones. |
| AID48346 | Beta-1-adrenoceptor antagonsim of compound expressed as inhibition of isoprenaline-induced tachycardia in the ganglion-blocked anesthetized cat | 1988 | Journal of medicinal chemistry, Feb, Volume: 31, Issue:2 | Design and synthesis of a series of combined vasodilator/beta-adrenoceptor antagonists based on 6-arylpyridazinones. |
| AID176932 | Dose required to produce a 50% increase in blood flow to the autoperfused hindquarters of the anesthetized rat | 1988 | Journal of medicinal chemistry, Feb, Volume: 31, Issue:2 | Design and synthesis of a series of combined vasodilator/beta-adrenoceptor antagonists based on 6-arylpyridazinones. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 40 (93.02) | 18.7374 |
| 1990's | 3 (6.98) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 16 (31.37%) | 5.53% |
| Reviews | 3 (5.88%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 32 (62.75%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||